Aileron Therapeutics, Inc. (ALRN) |
|
2.78 -0.12 (-4.14%)
|
02-03 14:08 |
|
Open: |
2.9 |
Pre. Close: |
2.9 |
|
High:
|
2.99 |
Low:
|
2.78 |
|
Volume:
|
30,200 |
Market Cap:
|
13(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:15:14 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.85 One year: 4.5 |
| Support: |
Support1: 2.36 Support2: 1.78 |
| Resistance: |
Resistance1: 3.29 Resistance2: 3.85 |
| Pivot: |
2.95  |
| Moving Average: |
MA(5): 2.82 MA(20): 2.91 
MA(100): 3.42 MA(250): 5.69 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 28.6 %D(3): 33.6 |
| RSI: |
RSI(14): 48 |
| 52-week: |
High: 15 Low: 0.26 |
| Average Vol(K): |
3-Month: 32 (K) 10-Days: 15 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALRN ] has closed above bottom band by 16.3%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3 - 3.02 |
3.02 - 3.04 |
|
Low:
|
2.84 - 2.86 |
2.86 - 2.88 |
|
Close:
|
2.87 - 2.9 |
2.9 - 2.93 |
|
Company Description |
|
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. |
Headline News |
Fri, 03 Feb 2023
Cancer progression pathway and possible therapy for Fanconi ... - BioWorld Online
Fri, 03 Feb 2023
ALERION AVIATION ADDS Bombardier Learjet 60 PRIVATE JET ... - Valdosta Daily Times
Thu, 10 Nov 2022
Aileron Therapeutics announces a 1-for-20 reverse stock split - Seeking Alpha
Wed, 26 Oct 2022
Aileron Therapeutics Presents Results from Phase 1 Study in ... - GlobeNewswire
Fri, 30 Sep 2022
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Mee - Yahoo Finance
Mon, 15 Aug 2022
Aileron Therapeutics Reports Second Quarter 2022 Financial ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
9 (%) |
|
% Held by Institutions
|
31.1 (%) |
|
Shares Short
|
15 (K) |
|
Shares Short P.Month
|
56 (K) |
Stock Financials |
|
EPS
|
-0.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-1.92 |
|
EPS Est Next Year
|
-1.88 |
|
Book Value (p.s.)
|
5 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-45.4 |
|
Return on Equity (ttm)
|
-81.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-3.75 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.52 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-27 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-9.12 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
0.55 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.48 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
